Merrill retains Alizyme at buy

Alizyme was retained by Merrill Lynch analyst Peter Welford at a buy rating based on positive phase 2b results from cetilistat (ATL-962) in Dec., putting Alizyme on track to partner the drug by mid-year, prior to phase 3 trials. Merrill expects a late 2009 launch and sales of more than $1.5 billion by 2012. Shares of the Cambridge, England, pharmaceutical company were up 7p, or 5.11%, at 144p on volume of 1,908,072 shares. (London: AZM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.